Full-Time
Lead Operations Manufacturing Mechanic
Updated on 8/23/2026
Becton Dickinson
10,001+ employees
Global medical devices and diagnostics provider
No salary listed
Sumter, SC, USA
In Person
Fully on-site in a manufacturing facility; must be willing to work any shift, including 12-hour night shifts.
Associate's
 General Maintenance & Repair (1) |
|---|
Get referred to Becton Dickinson
See people who can refer or advise you
- A high school diploma or GED is required.
- Mechanical proficiency and experience are required, including proficiency with basic hand tools.
- Knowledge of feeler gauges and other tools used to measure tolerances, torque, and clearances is required.
- At least one year of experience in a set-up or technical associate role, or equivalent experience, is required.
- Foundational knowledge of troubleshooting cams, cam-followers, rod-ends, bushings, chain drives, conveyors, gearboxes, vacuum systems, pneumatic systems, hydraulic systems, and ball valves is required.
- The candidate must demonstrate strong computer literacy, including proficiency with Microsoft Office Suite applications: Word, Excel, Outlook, and PowerPoint.
- Experience with email systems and digital communication platforms is required for daily operations, documentation, and cross-functional collaboration.
- The candidate must be able to stand, walk, bend, stoop, and climb stairs or ladders throughout the shift.
- The candidate must be able to lift and carry up to 50 pounds regularly without assistance and push or pull heavy equipment or carts as needed.
- Manual dexterity and hand-eye coordination are required to operate tools, controls, and machinery and to troubleshoot and repair equipment.
- Clear verbal communication is required for team coordination, safety alerts, and equipment troubleshooting.
- The candidate must be able to work in elevated temperatures, humidity, loud noise, and environments with chemical substances while using appropriate personal protective equipment.
- The candidate must safely navigate tight spaces and elevated platforms.
- The candidate must wear required personal protective equipment, including steel-toe shoes, safety glasses, gloves, and hearing protection.
- The candidate must be comfortable working independently and in team-based environments.
- The candidate must be willing and able to work any shift, including a 12-hour night shift.
- Operate, set up, adjust, perform changeovers on, troubleshoot, repair, and maintain all departmental production equipment.
- Be responsible for production, quality, downtime, and waste levels associated with machine operation.
- Provide informal leadership in a team environment.
- Train and advise technical associates and other associates on proper equipment setup and repair procedures.
- Train technical associates in methodical problem-solving techniques.
- Collaborate with engineering and automation control technicians to complete required projects.
- Use engineering, machine shop, production, and maintenance resources as required.
- Organize and direct improvement projects to increase equipment utilization in conjunction with area engineers, the manufacturing supervisor, and other required resources.
- Audit preventive maintenance procedures and activities performed by technical associates and other operations associates.
- Document preventive maintenance audits electronically and submit them to the supervisor for corrective action.
- Analyze equipment failures by frequency to modify or update preventive maintenance work orders.
- Set up and debug equipment according to documented specifications, escalating deviations to the supervisor or engineering.
- Maintain equipment in working order so products are produced within specified quality and quantity limits, adjusting, troubleshooting, cleaning, and repairing equipment as necessary.
- Maintain equipment logs for each piece of equipment, recording downtime and maintenance problems.
- Repair equipment and report major problems to the supervisor.
- Coordinate maintenance activities with the maintenance department, engineering, and other technical resources for major repair or production issues.
- Perform preventive maintenance according to the preventive maintenance program or as needed for smooth operation.
- Track and audit preventive maintenance tasks to ensure completion and closure in the SAP system.
- Turn on machines and verify that machines and control panels function properly.
- Ensure that safety guards are in position and working properly.
- Verify that part tracks and rails are clean to ensure free travel of component parts.
- Monitor production machinery to ensure optimal performance.
- Support upstream and downstream operations.
- Maintain the toolbox and keep the surrounding area neat and clean.
- Verify that equipment in surrounding areas is clean during the shift.
- Perform other duties as required.
- An Associate’s degree in Advanced Mechatronics Technology is preferred.
- Completed coursework in schematics, basic principles of mechanics, industrial electricity, problem solving for mechanical applications, and introduction to industrial technology is preferred; relevant experience may substitute for individual courses.
- Basic electrical knowledge and experience with programmable logic controllers, specifically Allen-Bradley systems, is preferred.
- Previous leadership or supervisory experience is preferred.
- The ability to learn and navigate SAP, root cause analysis tools, Tiered Management Systems, Total Productive Maintenance platforms, and key performance indicator tracking and analysis tools is expected.
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
- Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
- Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.
What critics are saying
- FDA classified BD’s intraosseous recall Class I on August 17, 2026.
- The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
- Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
- BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
- BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 10%1 year growth
↑ 10%2 year growth
↑ 10%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.